194 related articles for article (PubMed ID: 25367165)
1. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Citrome L; Weiden PJ; Alva G; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Winseck A
Clin Schizophr Relat Psychoses; 2015 Jan; 8(4):183-95. PubMed ID: 25367165
[TBL] [Abstract][Full Text] [Related]
2. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Weiden PJ; Citrome L; Alva G; Brams M; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Pestreich L; Hochfeld M; Winseck A
Schizophr Res; 2014 Mar; 153(1-3):160-8. PubMed ID: 24529610
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
4. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
5. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
6. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
[TBL] [Abstract][Full Text] [Related]
8. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
[TBL] [Abstract][Full Text] [Related]
9. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.
Casey DE; Carson WH; Saha AR; Liebeskind A; Ali MW; Jody D; Ingenito GG;
Psychopharmacology (Berl); 2003 Apr; 166(4):391-9. PubMed ID: 12610718
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Cutler AJ; Kalali AH; Mattingly GW; Kunovac J; Meng X
CNS Spectr; 2013 Feb; 18(1):43-54. PubMed ID: 23312567
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of iloperidone in the treatment of schizophrenia.
Dargani NV; Malhotra AK
Expert Opin Drug Saf; 2014 Feb; 13(2):241-6. PubMed ID: 24206391
[TBL] [Abstract][Full Text] [Related]
12. Iloperidone for the treatment of schizophrenia.
Marino J; Caballero J
Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
Weiden PJ; Manning R; Wolfgang CD; Ryan JM; Mancione L; Han G; Ahmed S; Mayo MG
CNS Drugs; 2016 Aug; 30(8):735-47. PubMed ID: 27379654
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Potkin SG; Litman RE; Torres R; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
17. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
18. Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period.
Weiden PJ; Du Y; Liu CC; Stanford AD
CNS Spectr; 2019 Aug; 24(4):419-425. PubMed ID: 29941057
[TBL] [Abstract][Full Text] [Related]
19. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
[TBL] [Abstract][Full Text] [Related]
20. Iloperidone: A new drug for the treatment of schizophrenia.
Arif SA; Mitchell MM
Am J Health Syst Pharm; 2011 Feb; 68(4):301-8. PubMed ID: 21289324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
